SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-070574
Filing Date
2023-12-15
Accepted
2023-12-15 07:30:09
Documents
15
Period of Report
2023-12-11
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acst-20231211.htm   iXBRL 8-K 44091
2 EX-16.1 acst-ex16_1.htm EX-16.1 8275
3 GRAPHIC img51618503_0.jpg GRAPHIC 2832
4 GRAPHIC img51618503_1.jpg GRAPHIC 7504
  Complete submission text file 0000950170-23-070574.txt   185777

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT acst-20231211_pre.xml EX-101.PRE 9851
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT acst-20231211.xsd EX-101.SCH 2481
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT acst-20231211_lab.xml EX-101.LAB 13352
9 EXTRACTED XBRL INSTANCE DOCUMENT acst-20231211_htm.xml XML 4701
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-649-9272
Acasti Pharma Inc. (Filer) CIK: 0001444192 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 231488772
SIC: 2834 Pharmaceutical Preparations